What is HC Wainwright's Forecast for IOVA Q3 Earnings?

Key Points

• HC Wainwright raised its Q3 2026 EPS estimate for Iovance Biotherapeutics to a loss of $0.12 per share from a prior estimate of $0.17, while projecting losses of $0.16 for Q4 2026 and $0.35 for FY2027.
• Iovance recently beat quarterly expectations, reporting a $0.11-per-share loss versus the $0.13 consensus estimate and revenue of $198.63 million, up 65.7% year over year.
• Analyst sentiment remains mixed: the stock has a consensus “Hold” rating and an average $8 price target, despite recent target increases and stronger Amtagvi demand. Iovance remains unprofitable, with ongoing commercialization and clinical-trial risks.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - Research analysts at HC Wainwright increased their Q3 2026 EPS estimates for shares of Iovance Biotherapeutics in a research note issued on Thursday, August 6th. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will earn ($0.12) per share for the quarter, up from their previous estimate of ($0.17). The consensus estimate for Iovance Biotherapeutics' current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for Iovance Biotherapeutics' Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.58) EPS and FY2027 earnings at ($0.35) EPS.

IOVA has been the subject of several other reports. Citigroup restated an "outperform" rating on shares of Iovance Biotherapeutics in a research report on Friday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Iovance Biotherapeutics in a report on Thursday, July 2nd. Barclays raised their target price on Iovance Biotherapeutics from $11.00 to $13.00 and gave the company an "overweight" rating in a report on Friday. Citizens Jmp boosted their price target on shares of Iovance Biotherapeutics from $5.00 to $8.00 and gave the stock a "market outperform" rating in a research note on Friday. Finally, Chardan Capital lowered their price objective on shares of Iovance Biotherapeutics from $16.00 to $14.00 and set a "buy" rating for the company in a research note on Thursday, May 7th. Five analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat, Iovance Biotherapeutics currently has a consensus rating of "Hold" and an average price target of $8.00.

Iovance Biotherapeutics Price Performance

Shares of NASDAQ IOVA opened at $6.34 on Monday. The business's 50 day moving average is $4.40 and its two-hundred day moving average is $3.81. Iovance Biotherapeutics has a 52-week low of $1.76 and a 52-week high of $6.92. The firm has a market cap of $2.87 billion, a price-to-earnings ratio of -8.68 and a beta of 0.71.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.13) by $0.02. Iovance Biotherapeutics had a negative net margin of 89.11% and a negative return on equity of 40.92%. The firm had revenue of $198.63 million during the quarter, compared to analysts' expectations of $87.83 million. During the same quarter last year, the company posted ($0.33) EPS. The firm's quarterly revenue was up 65.7% on a year-over-year basis.

Hedge Funds Weigh In On Iovance Biotherapeutics

Several institutional investors have recently added to or reduced their stakes in IOVA. Arcataur Capital Management LLC purchased a new position in Iovance Biotherapeutics in the fourth quarter worth $29,000. Granite Investment Partners LLC acquired a new position in shares of Iovance Biotherapeutics during the 4th quarter worth $29,000. Motley Fool Asset Management LLC purchased a new position in shares of Iovance Biotherapeutics in the 4th quarter valued at about $29,000. M&T Bank Corp acquired a new stake in shares of Iovance Biotherapeutics in the fourth quarter valued at about $31,000. Finally, SBI Securities Co. Ltd. boosted its holdings in Iovance Biotherapeutics by 169.1% during the fourth quarter. SBI Securities Co. Ltd. now owns 11,568 shares of the biotechnology company's stock worth $32,000 after buying an additional 7,269 shares in the last quarter. Institutional investors and hedge funds own 77.03% of the company's stock.

Key Headlines Impacting Iovance Biotherapeutics

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Record revenue and strong Amtagvi demand: Second-quarter revenue reached approximately $99.3 million, up 66% year over year and well above analyst expectations. U.S. Amtagvi revenue was about $91 million, rising 40% from the fourth quarter, helping drive the earnings beat. Iovance Q2 2026 results
• Positive Sentiment: Loss narrowed and margins improved: Iovance reported a loss of $0.11 per share, better than the $0.13–$0.17 consensus range and an improvement from $0.33 per share a year earlier. Gross margin increased to 56% as manufacturing and cost efficiencies improved. Zacks Q2 earnings report
• Positive Sentiment: Analyst support strengthened: Citizens JMP raised its IOVA price target from $5 to $8 and assigned a “market outperform” rating, reinforcing bullish sentiment following the results. Benzinga analyst update
• Positive Sentiment: Pipeline catalysts expanded: The FDA granted Fast Track Designation to lifileucel for soft tissue sarcomas. Investors are also focused on upcoming data from melanoma and non-small-cell lung cancer programs, with additional trial updates expected later this year. Iovance pipeline update
• Neutral Sentiment: Management is reviewing its 2026 revenue outlook of $350 million to $370 million because of stronger demand, but plans to provide an updated forecast in the third quarter. The company ended June with approximately $304 million in cash, expected to fund operations into the second half of 2028.
• Negative Sentiment: Iovance remains unprofitable, posting a quarterly net loss of approximately $47.3 million, while research and development expenses totaled $58.9 million. Continued losses and execution risks around commercialization and clinical trials remain important risks for investors.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company's lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance's pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance's TIL platform harnesses a patient's own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source